Safety and Immunogenicity of a Novel Trivalent Recombinant MVA-Based Equine Encephalitis Virus Vaccine: A Phase 1 Clinical Trial

A novel multivalent MVA-BN-WEV vaccine encodes the envelope surface proteins of the 3 viruses and is thereby potentially able to protect against three encephalitic alphaviruses. This first-in-human study assessed the safety, tolerability, and immunogenicity of MVA-BN-WEV vaccine in healthy adult participants.